Features | Partner Sites | Information | LinkXpress
Sign In
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC
Demo Company

2013 JIB Congress to Emphasize New Perspectives in Medical Biology

By BiotechDaily International staff writers
Posted on 15 Jul 2013
A new governance has been set up to organize the next Journées Internationales de Biologie (JIB; Paris, France), its 58th annual meeting of medical biologists, to be held November 13–15, 2013 at the CNIT Paris, La Défense. In order to place the congress as a key "laboratory agenda" professional event, JIB renews itself not only as a recurring gathering for the profession, but also as an opportunity to gain fresh, positive perspectives on one's daily practice in the laboratory.

In order to optimize attendee presence at the meeting, efficiency is emphasized in enabling participants in each area to gather, individually or collectively, in a productive manner. Medical biologists can find solutions in various missions (HR, quality, logistics, finance, etc.) and fields (hematology, virology, biochemistry, etc.) by their participation in the congress, the exhibition, and the JIB Awards. Discussions and exchanges between specialists take place on the "Paroles d’Experts.” The "Institutions Corner" brings together various authorities for the profession (regional associations, societies, orders, ministries, syndicates, or humanitarians). JIB is also committed to the new generation and has dedicated the "Recruitment Sphere" section with practical workshops to help facilitate access and integration of new biologists to the professional world.

The exhibition platform for launching innovations will present nearly 200 technological advances and solutions, of which 75% have a European and worldwide scope, and 78% are presented for the first time. Innovation is particularly visible at the "Innovation Gallery," and is further emphasized at the JIB Awards ceremony, provided for the second time after its success in 2012, now with six new categories: Procedures Improvement, Innovation Gallery, Quality and Accreditation, Emergency Biology and POC, Post Analytics Innovation, and the Jury’s Award.

The congress sessions mainly relate to the multidisciplinary aspect of medical biology, innovative laboratory equipment and technologies, and the role of biology in healthcare policies and organization. The inaugural session “Medical biology and screening policies” highlights biology in preventive and individualized medicine as the desired alternative to curative medicine. The session on “Nanotechnologies, first outcomes and perspectives in medical biology” presents an overview of the miniaturized technologies that are transforming diagnosis and follow-up methods. In parallel to the scientific sessions, the "Colloquium" offers working sessions to assist with various topics such as laboratory services, the medical biology laboratory in local health policies, and the evolution of the biomedical practice organization.

Related Links:

JIB - Journées Internationales de Biologie





Channels

Genomics/Proteomics

view channel
Image: An activated PTEN dimer that contains two non-mutant proteins (A) can transform the functional lipid (D) on the cellular membrane (E) into a chemical form that tunes down cancer predilection. Dimers that contain a mutated protein (B) or PTEN monomers cannot transform the functional lipid (Photo courtesy of Carnegie Mellon University).

PTEN Requires a Stable Dimer Configuration to Effectively Suppress Tumor Growth

Molecular structural analysis has shown that the PTEN (phosphatase and tensin homolog) tumor suppressor can function effectively only when two wild-type alleles are present to form a stable dimer that... Read more

Lab Technologies

view channel
Image: The VIAFLO Assist pipette adapter (Photo courtesy of INTEGRA Biosciences).

Pipetting Assistant Helps Prevent Repetitive Strain Injuries

A powerful pipetting accessory makes life easier for technicians in both clinical and research laboratories. Prolonged and repetitive pipetting sessions bear the risk of strain and fatigue, often resulting... Read more

Business

view channel

MS Drug Deal to Net More Than USD 1 Billion

A pharmaceutical company based in Switzerland has purchased the remaining rights to the multiple sclerosis drug Ofatumumab, which will allow it to continue development of the compound for treating relapsing remitting multiple sclerosis (RRMS) and similar autoimmune diseases. Novartis (Basel, Switzerland) recently announced... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.